HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Catalyst Pharmaceuticals (CPRX) and raises the price target from $24 to $26.
May 10, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with an increased price target from $24 to $26, indicating positive analyst sentiment and potential upside.
The increase in price target by HC Wainwright & Co. reflects a positive outlook on Catalyst Pharmaceuticals, suggesting that the analyst sees potential for the stock to grow beyond its current price. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100